Peter Attia· MD
so again typically very small studies uh can be you know in the 20 30 40 50 range maybe up to a few hundred people and that one peter i think is a probably a good example of if you have the non-randomization this might be a case where say it's an immunotherapy and people know about the immunotherapy and it's been really effective for a particular gets approved for a particular cancer let's say and there are a lot of people that know about it and there are cancer patients that know about it and they want to get that treatment but it's not approved if they're talking to their doctor they or maybe they're online they might enroll in one of these trials because they really want to try the drug and maybe they you know they might believe in it more than than some other treatment yep yeah there are lots of things that can introduce bias to a phase 2 if it does not have randomization